Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the second line therapy of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma

Inclusion Criteria:

• Doctor's decision to prescribe Ribomustin and rituximab combined therapy for the treatment of relapsed or refractory indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
• Informed Consent Form for personal data handling signed by the program participant, authorized by the Independent Ethics Committee
• Eastern Cooperative Oncology Group (ECOG) status < 2.
• Confirmed relapse or disease progression of B-cell CD20+ Non-Hodgkin's Lymphoma (lymphocytic, lymphocytoplasmocytic, follicular, marginal zone) after minimum one line of iNHL treatment
• Patients with relapsed or refractory indolent B-cell Non-Hodgkin's Lymphoma with current or planned Ribomustin and rituximab combined therapy with following rituximab maintenance therapy

Exclusion Criteria:

• Indolent Non-Hodgkin's Lymphoma transformation
• Lymphoma with central nervous system (CNS) involvement
• Presence of second malignant tumor.
• Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment.
• Contraindications for Ribomustin usage in accordance with product label
• Contradictions for rituximab usage in accordance with product label

Patients with Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma with planned combined Ribomustin and rituximab therapy